SCHEMBL5402174

SCHEMBL5402174

CNc1nc([S+](C)[O-])ncc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 2/20 0.36
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
LRRK2 Q5S007 5/20 0.34
ACVR2A P27037 1/20 0.32
TGFBR1 P36897 1/20 0.32
TGFBR2 P37173 1/20 0.32
LMNA P02545 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
TRPM8 Q7Z2W7 2/20 0.31
MITF O75030 1/20 0.31
MAPT P10636 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KDM4E B2RXH2 2/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407960 0.77 CYP1A2 (0.30) CYP1A2CYP3A4CYP2D6
SCHEMBL5410513 0.76 NPC1 (0.37) ALDH1A1LMNASMN1; SMN2MAPTMAPK1
SCHEMBL26803312 0.73 PGK1 (0.41) PGK1ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL14556227 0.72 ALDH1A1 (0.49) PGK1ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL5408100 0.70 TDO2 (0.37) ALDH1A1CYP1A2CYP3A4HSD17B10TDP1
SCHEMBL5411406 0.69 KDM4E (0.56) PGK1ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL16120495 0.68
SCHEMBL17709574 0.68
SCHEMBL16094186 0.67 RXRA (0.34) ALDH1A1LMNAMITFMAPTMAPK1
SCHEMBL16094735 0.67 LMNA (0.33) CYP1A2LMNASMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 US disclosed
EP-1453516-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-09-08 EP disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 US disclosed
WO-2003032994-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 PGK1 1897/4885ALDH1A1 753/4885CYP1A2 409/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 PGK1 1832/4885ALDH1A1 681/4885CYP1A2 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.